biotech stock poised for growth in ATTR-CM market By Investing.com
Alnylam Pharmaceuticals , Inc. (NASDAQ:), a leader in RNA interference (RNAi) therapeutics, stands at a pivotal moment in its corporate journey. With its flagship product Amvuttra (vutrisiran) poised for potential approval in the treatment of transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM), the company is on the cusp of entering a lucrative market that could significantly boost its financial performance and market position.
Company Overview and Market Position
Alnylam has established itself as a pioneer in the field of RNAi therapeutics, with a focus on rare and genetic diseases. The company’s current product portfolio includes four FDA/EMA-approved drugs for rare diseases, positioning it well in the biotechnology sector….
